Odds-On-Favorite Ubl Confirmed As Next PhRMA CEO
This article was originally published in Scrip
The Pharmaceutical Research and Manufacturers of America (PhRMA) late on Sept. 25 confirmed what had been widely speculated about in Washington and among industry insiders that AdvaMed CEO Stephen Ubl would be taking the reins as the next chief of the drug lobbying group.
You may also be interested in...
PhRMA CEO Stephen Ubl visited Allergan's Irvine, Calif. R&D and manufacturing campus as the trade association continues its "Go Boldly" campaign promoting biopharma innovation in an effort to counteract the hit the industry's reputation has taken from drug pricing concerns.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.